- Home
- BANR vs GENB Comparison
BANR vs GENB Comparison
Compare BANR & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | BANR | GENB |
|---|---|---|
| Founded | 1890 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.9B |
| IPO Year | 2015 | 2026 |
Fundamental Metrics
Financial Performance| Metric | BANR | GENB |
|---|---|---|
| Price | $70.46 | $15.41 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $70.00 | $23.20 |
| AVG Volume (30 Days) | 290.3K | ★ 1.1M |
| Earning Date | 04-22-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.14% | N/A |
| EPS Growth | ★ 15.57 | N/A |
| EPS | ★ 3.03 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.73 | N/A |
| Revenue Next Year | $5.69 | $16.58 |
| P/E Ratio | $23.16 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $57.05 | $11.00 |
| 52 Week High | $74.84 | $22.67 |
Technical Indicators
Market Signals| Indicator | BANR | GENB |
|---|---|---|
| Relative Strength Index (RSI) | 47.58 | 50.75 |
| Support Level | $62.40 | $12.05 |
| Resistance Level | $72.65 | $17.46 |
| Average True Range (ATR) | 1.26 | 1.63 |
| MACD | -0.40 | 0.03 |
| Stochastic Oscillator | 20.07 | 20.05 |
Price Performance
Historical ComparisonAbout BANR Banner Corporation
Banner Corp is a bank holding company. It wholly owns one subsidiary bank, Banner Bank. The Bank's primary business is that of traditional banking institutions, accepting deposits and originating loans in locations surrounding its offices in Washington, Oregon, California, Idaho, and Utah. Banner Bank also actively participates in the secondary loan markets, engaging in mortgage banking operations largely through the origination and sale of one to four family residential loans.
About GENB Generate Biomedicines Inc. Common Stock
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.